Ebixa indications extended

15 December 2005

The licensed indications for Ebixa (memantine) have been extended to allow its use in the treatment of moderate to severe Alzheimer's dementia. Previously, Ebixa's uses were limited to the treatment of moderately severe to severe Alzheimer's dementia.

The extension to Ebixa's licence follows a meta-analysis of patients with moderate to severe Alzheimer's dementia from six phase III, placebo-controlled, 6-month studies which showed that memantine had a significantly favourable effect in preventing worsening of cognitive, global and functional domains.

Memantine is an NMDA receptor antagonist that modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.

View Ebixa drug record

Further Information: Lundbeck Ltd